In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more
ACVC Clinical Decision-Making Toolkit

One of the best tools to help practitioners make the best bedside clinical decisions when managing patients with acute cardiovascular disease.

See more
Be Guidelines Smart

A comprehensive guidelines implementation toolkit especially for Nurses & Allied Professionals. 

See more

Acknowledgements

The ESC Prevention of CVD Programme is led by a project management group, overseeing coordinators and contributors for each work package.

Experts from the European Association of Preventive Cardiology (EAPC), Association for Acute CardioVascular Care (ACVC) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP) are involved in all stages of the programme development.

Project Management Group

  • Nicolle Kränkel (EAPC)-  Project Leader
  • Marco Guazzi (EAPC) - Deputy Project Leader
  • Maddalena Lettino (ACVC) - Coordinator
  • Susanna Price (ACVC) - Deputy Coordinator
  • Catriona Jennings (ACNAP) - Coordinator
  • Donna Fitzsimons (ACNAP) - Deputy Coordinator

Phase III: Continued Roll-out, Evaluation and Follow-up

Work Package Coordinators and Contributors (2018-2019)

Work Package 1: Awareness

Coordinators

  • Konstantin Krychtiuk
  • Silvia Castelletti

Contributors

  • Paul Dendale (EAPC)
  • Mary Kerins (ACNAP)
  • Ines Frederix (EAPC)
  • Flavio D'Ascenzi (EAPC)
Work Package 2: Setting Standards / Audit

Coordinator

  • Arno Hoes

Contributors

  • Kasia Czerwinska (ACVC)
  • Anna Oleksiak (ACVC)
  • Izabella Uchmanowicz (ACNAP)
  • Gabrielle McKee (ACNAP)
  • Margrét Hrönn Svavarsdóttir (ACNAP)
  • Advisor: Ian Graham
Work Package 3 : Implementation Tools

Coordinator

  • Arne Janssen

Contributors

  • Xavier Rossello (ACVC)
  • Ekaterini Lambrinou (ACNAP)
  • Advisors: Jannick Dorresteijn / Frank Visseren

Phase II: Focus on Secondary Prevention (January 2016 - June 2017)

Work Package Coordinators and Contributors

Webinars & online education
  • Lale Tokgozoglu (EAPC) - Coordinator
  • Ingo Ahrens (ACVC)
  • Eleni Kletsiou (ACNAP)
Masterclasses
  • Jean-Paul Schmid (EAPC) - Coordinator 
  • Kurt Huber (ACVC)
  • Gabrielle McKee (ACNAP)
Web
  • Paul Dendale (EAPC) - Coordinator
  • Konstantin Krychtiuk (ACVC)
  • Mary Kerins (ACNAP)
Scientific resources
  • Massimo Piepoli (EAPC) - Coordinator
  • David Walker (ACVC)
  • Donna Fitzsimons (ACNAP)
Patient survey
  • Catriona Jennings (ACNAP) - Coordinator
  • Eva Prescott (EAPC)
  • Chris Gale (ACVC)
  • Felicity Astin & Tina Hansen (ACNAP)
EJPC Supplement
  • Diederick Grobbee (EAPC) - EJPC Editor in Chief & Coordinator
  • Marco Guazzi (EAPC) - Guest Editor
  • Christiaan Vrints (ACVC) - Guest Editor
  • Ekaterini Lambrinou (ACNAP) - Guest Editor
National CVD Prevention Coordinators workshop
  • Arno Hoes (EAPC) - Coordinator
  • Sergio Leonardi (ACVC)
  • Catriona Jennings (ACNAP)

Phase I: Secondary Prevention after Myocardial Infarction (2015)

Web Work Package Group

  • Paul Dendale - Jessa Hospital, Hasselt, Belgium
  • Konstantin Krychtiuk - Medical University of Vienna, Vienna, Austria
  • Mary Kerins - St James's Hospital, Dublin 8
  • Ines Frederix (Global reviewer): (1) Jessa Hospital, Department of Cardiology, Hasselt, Belgium
    (2) Hasselt University, Faculty of Medicine & Life Sciences, Hasselt, Belgium
    (3) Antwerp University, Faculty of Medicine & Health Sciences, Antwerp, Belgium 

IHD in your country

First author
  • Lene Rørholm Pedersen - University Hospital of Sealand, Roskilde, Denmark
  • Eva Prescott - Professor, Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
Reviewer
  • Mary Kerins - St James's Hospital, Dublin 8

Risk assessment

First author
  • Visseren FL - University Medical Center Utrecht, The Netherlands
  • J Dorresteijn - University Medical Center Utrecht, The Netherlands
Reviewer
  • Gabrielle Mckee - School of Nursing & Midwifery Trinity College Dublin

How to approach your patient

First author
  • Izabella Uchmanowicz - Wroclaw Medical University, Poland
Reviewer
  • Ugo Corra - Istituti Clinici Salvatore Maugeri, Veruno, Italy

Treatment goals

First author
  • Massimo Piepoli - Cardiology, Guglielmo da Saliceto Hospital, Piacenza, Italy
Reviewer
  • Jeroen Hendriks - Centre for Heart Rhythm Disorders, University of Adelaide, South Australian Health and Medical Research Institute and Royal Adelaide Hospital, Australia

Cardioprotective drugs - antiplatelets

First author
  • Pascal Vranckx - Heart Center Hasselt, Hasselt, Belgium
Reviewer
  • Kurt Huber - Wilhelminen Hospital Vienna, Vienna, Austria

Cardioprotective drugs - ACE-I / ARBS

First author
  • Héctor Bueno - Hospital Universitario 12 de Octubre, Madrid, Spain
  • Roberto Martin Asenjo - Hospital Universitario 12 de Octubre, Madrid, Spai
Reviewer
  • Michael Mcintosh - University of Sheffield, United Kingdom

Cardioprotective drugs - beta-blocker

First author
  • Ines Frederix: (1) Jessa Hospital, Department of Cardiology, Hasselt, Belgium
    (2) Hasselt University, Faculty of Medicine & Life Sciences, Hasselt, Belgium
    (3) Antwerp University, Faculty of Medicine & Health Sciences, Antwerp, Belgium
Reviewer
  • Michael Macintosh - University of Sheffield, United Kingdom

Cardioprotective drugs - statins

First author
  • Konstantin Krychtiuk - Medical University of Vienna, Vienna, Austria
Reviewer
  • Walter S. Speidl - Medical University of Vienna, Vienna, Austria

Cardioprotective drugs - polypills

First author
  • Diederick E. Grobbee - Julius Center for Health Sciences and Primary Care, Clinical Epidemiology, University Medical Center Utrecht, Netherlands

Risk factor control - blood pressure

First author
  • Guy De Backer - Department of Cardiology, Ghent University Hospital, Ghent, Belgium
  • Tine De Backer - Department of Cardiology, Ghent University Hospital, Ghent, Belgium
Reviewer
  • Christiaan Vrints - Department of Cardiology, Antwerp University, Antwerp, Belgium

Risk factor control - lipids

First author
  • Olov Wiklund Wallenberg - Laboratory, Sahlgrenska University Hospital, Göteborg, Sweden
Reviewer
  • Ana Abreu - Hospital Santa Marta, CHLC, Lisbon, Portugal

Risk factor control - glycemic

First author
  • Josef Niebauer - Institute of Sports Medicine of the State of Salzburg, Salzburg, Austria
Reviewer
  • Paul Dendale - Jessa Hospital, Hasselt, Belgium

Risk factor control - weight

First author
  • Gabriele Riccardi Federico - II University, Naples, Italy
Reviewer
  • Paul Dendale - Jessa Hospital, Hasselt, Belgium

Risk factor control - smoking

First author
  • Vassilis Vassiliou - Norwich Medical School and Imperial College London, UK
Reviewer
  • Paul Dendale - Jessa Hospital, Hasselt, Belgium

Risk factor control - nutrition

First author
  • Claire Kerins - School of Health Sciences, National University of Ireland Galway, University Road, Galway, Ireland.
Reviewer
  • Demosthenes B. Panagiotakos - School of Health Science & Education, Harokopio University, Athens - Kalithea, Greece

Risk factor control - physical exercise

First author
  • Dominique Hansen - Hasselt University - Campus, Diepenbeek, Belgium
Reviewer
  • Paul Dendale - Jessa Hospital, Hasselt, Belgium

Cardiac rehabilitation and exercise training recommendations

First author
  • Maria Back - Institute and the Medical and Health Sciences, Linkoping, Sweden
  • Tina Hansen - Zealand University Hospital, Department of Cardiology, Denmark
Reviewer
  • Ines Frederix: (1) Jessa Hospital, Department of Cardiology, Hasselt, Belgium
    (2) Hasselt University, Faculty of Medicine & Life Sciences, Hasselt, Belgium
    (3) Antwerp University, Faculty of Medicine & Health Sciences, Antwerp, Belgium

The ESC Prevention of Cardiovascular Disease programme is supported by AMGEN, AstraZeneca, Ferrer for good, and Sanofi and Regeneron in the form of educational grants.